Black Diamond Therapeutics Inc (BDTX)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a...

Form 8-K - Current report

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed...

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE...

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients...

Form S-8 - Securities to be offered to employees in employee benefit plans